Tag: ALT

  • Crypto Weekly Winners: ATH Coins and Top Movers (24H)

    Crypto Weekly Winners: ATH Coins and Top Movers (24H)

    With market sentiment at a point higher than was ever seen throughout most of 2022, bulls in the market did not hold back and took their favorite crypto-names launching to new heights. With this winning momentum, several cryptocurrencies broke all records and established new all-time highs. At the time of writing this newsletter, these ATH coins are as follows:

    Crypto

    ATH coins

    Aptos

    Aptos (APT) is the most important name on this list of ATH performers because it not only established an all-time high in its price but also in its trade volume, which recently surpassed the $2.9 billion mark. APT has been in the trade since mid-November and has been falling to as low as $3, during this period. Its present surge has taken it up to an all-time high of $19.36, which it is likely to continue surpassing throughout the day. Aptos stands as the 25th largest cryptocurrency, and hence its surge in the wake of bullish sentiment comes as expected, as the market overall turns toward a buying momentum.

    Gains Farm

    Gains Farm (GFARM2) has also shown an impressive rise, putting it up to a magnificent all-time high of almost $6000, earlier today. To put this achievement in context, GFARM2 has been in the market since mid-2021, and initiated at $94. The year brought several high points and subsequent corrections, with shifting confidence surrounding the project. Its recent surge comes after a 400% volume increase, indicating a coordinated price pump, without any apparent updates to the Gains Farm project.

    Gains Network 

    Gains Network (GNS) has seen a tremendous upward price explosion which brought it up to a new record high of $6. The project has been seeing growing interest throughout the prior weeks after it announced a partnership with Trader Joe’s to enable zero slippage trading and concentrated liquidity provisions. Volume too has been rising at a stellar pace in recent days from $1 million to its present level of $5.7 million.

    MASQ

    MASQ made it to $0.3915 earlier today, slightly scraping above an earlier high point of $0.3869 it had achieved in early 2021. Since then it has been rising and falling on par with the overall sentiment seen with the wider crypto-market. Its recent rise corresponds with a drastic improvement in market sentiment, pushing into the green zone. The project’s launch of a fully decentralized web browser further adds to the hype surrounding it.

    Atlas Navi

    Atlas Navi (NAVI) has been on a downward slump throughout most of December in 2022 and much of January, falling to as low as $0.0432 during this time. However, NAVI has been on a roll during the last 5 days, as its volume peaked at over $2.7 million, causing its price to take off spectacularly. Guided by strong fundamentals such as 350,000 app downloads and a circulation of over 10 million, bulls raised this crypto-name to a new high of $0.1837.

    Top Movers (24H)

    Just like how the excellent state of market sentiment has yielded top winners in terms of ATH coins, several have performed well in terms of their daily price movements. Based on this metric, several have outperformed their crypto-peers, and have become top movers of the day. At the time of writing this newsletter, these winners are as follows:

    Shih Tzu Inu

    Shih Tzu Inu (SHIH-TZU) has been seeing an impressive price jump today, which took it up by 258% in a single day, ballooning it beyond three times its price seen yesterday. Market participants seem fascinated by the project, and expect it not to come crashing down, considering that its liquidity has been locked until October 2023, hence the mass accumulation. Its growing volume trend indicates that SHIH-TZU may yet rise to even further new highs throughout the day.

    Xoloitzcuintli

    Xoloitzcuintli (XOLO), has seen quite the rise today, almost consistent with the increase in its volume in recent hours. XOLO more than doubled its price from $0.000046 to $0.000095 in a matter of hours, as its trading volume more than quadrupled from $370,000 to $1.5 million. The market is rushing towards the XOLO market for the purposes of trading Ethereum and related tokens with low gas fees, hence the mass ‘buy and hold’ strategy at play here.

    AptosLaunch Token

    AptosLaunch Token (ALT) also caught a share of the glory among today’s list of winners, as the wider Aptos ecosystem continues to deliver stellar wins this week. ALT rose impressively from $0.061 to $0.140, translating to a single-day gain of 130%. Volume too has risen explosively from $360,000 to $3.6 million, in barely 24 hours. This surge comes as Aptos and Move plan to launch Spaceport later today, which it claims will prove itself as crypto’s largest incubation program. It has already got on board 26 venture capitalists who will be judging between 16 different projects.

    Blocksport

    Blocksport (BSPT), following a full week of price stability and barely any movement, exploded upwards today from $0.00053 to $0.00233. This sudden jump of 340% remained short-lived, however, as the high peak of this price pump could not sustain itself during the day. However, even after its price correction, BSPT is trading at an impressive $0.00093, which is 73% higher than its corresponding price seen yesterday. Only time will tell if this pump will continue throughout the day.

    ROOBEE

    ROOBEE, has been pushing on with its upward momentum of the last two weeks by further delivering a 50% price jump in the last two hours. In its slow and steady rise, this blockchain-based investment platform has successfully multiplied its price by a factor of 2.5 in the last month. Furthermore, its growing volume trend suggests that the rise is far from over, and the trend may very well continue for at least the upcoming several days.

  • Here is why Altimmune Inc (ALT) stock sink on Tuesday?

    Here is why Altimmune Inc (ALT) stock sink on Tuesday?

    Altimmune Inc. (ALT) shares plummeted 38.18% in after-hours on Tuesday, June 29, 2021, and closed at $9.83 per share. Earlier in the morning session, ALT’s stock lost 2.45% to close Tuesday’s session at $15.90. ALT shares have risen 52.59% over the last 12 months, and they have moved up 2.19% in the past week. Over the past three months, the stock has gained 17.34%, while over the past six months, it has lost 43.24%.

    The disappointing outcome of AdCOVID™ Phase 1 Clinical Trial

    On June 29, 2021, Altimmune, Inc provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The Company also provided an update on its T-COVID Phase 1/2 clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19.

    80 healthy adult volunteers between the ages of 18 and 55 took part in Phase 1 AdCOVID clinical trial. The volunteers received either 1 or 2 doses of AdCOVID as a nasal spray at 3 dose levels.

    The data showed lower than expected immune responses for each of the immune parameters tested. The magnitude of the response and the percent of subjects responding to AdCOVID were substantially lower than what had been demonstrated for other vaccines already authorized for emergency use.

    Due to poor trial 1 results, Altimmune is discontinuing further development of AdCOVID beyond the completion of this Phase 1 trial.

    Positive Interim Data from ALT-801 Phase 1 Trial

    On June 16, 2021, Altimmune, Inc announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801, an investigational GLP-1/glucagon dual receptor agonist, in healthy overweight and obese volunteers. The study is currently being conducted in Australia under a clinical trial application.

    The results showed that a mean weight loss of 5.4% was achieved by Week 6 with a once-weekly ALT-801 dose of 1.8 mg compared to a weight gain of 0.9% in the placebo group.

    Recent financial results

    On May 17, 2021, Altimmune, Inc released its financial results for the three months ending March 31, 2021.

    Q1 2021 financial highlights

    • Altimmune reported revenue of $0.8 million for Q1 2021 compared to $2.2 million inQ1 2020.
    • The company spent $11.9 million in research and development expenses in Q1 2021 compared to $7.2 million in Q1 2020.
    • General and administrative expenses were $3.8 million in Q1 2021 compared to $2.3 million in Q1 2020.
    • The company suffered a net loss of $14.9 million, or $0.38 net loss per share in Q1 2021, compared to $3.9 million, or $0.26 net loss per share in Q1 2020.
    • As of March 31, 2021, Altimmune had cash, cash equivalents, and short-term investments totalling $226.5 million compared to $216.0 million on December 31, 2020.

    Conclusion

    The poor trial one results of the Covid-19 vaccine candidate took the ALT stock to rock bottom. The plummeting can continue on Wednesday as well.